Literature DB >> 16308704

Clinical characteristics and surgical treatment of perianal and perineal rhabdomyosarcoma: analysis of Japanese patients and comparison with IRSG reports.

Kaori Okamura1, Hideki Yamamoto, Yuki Ishimaru, Hajime Takayasu, Yushi Otani, Junko Yamagishi, Atsushi Takahashi, Hiroyuki Kuwano, Kikuo Nagashima, Hitoshi Ikeda.   

Abstract

Rhabdomyosarcomas of the perianal and perineal regions are uncommon. This study was performed to clarify the clinical characteristics and guidelines of surgical treatment of patients with perianal and perineal rhabdomyosarcomas younger than 20 years of age. Twenty-nine patients, 26 patients identified in the Japanese literature and three of our own, were analyzed and the results were compared with the data reported from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Female predominance and a twin-peak age distribution in infancy and adolescence were characteristic findings of the Japanese patients that were not observed in the IRSG studies. The demographic differences between the two groups were attributed to the differences in demographics of patients younger than 10 years of age. Of the 29 patients, 17 were categorized into clinical groups III/IV and 21 patients into stages 3/4. Alveolar histology was diagnosed in 18 patients. In patients more than 10 years of age, the female predominance was more prominent and the incidences of advanced clinical groups/stages and alveolar histology were significantly higher than those in patients younger than 10 years of age. Inguinal lymph nodes were always involved in patients with lymph node metastases and three patients developed metastases to the breast. Information regarding the survival time was available for 18 patients and the 5-year overall survival was 20%. Two patients with a group I/stage 2 tumor and one with a group II/stage 3 tumor survived for more than 2 years with no evidence of the disease. In these patients, the tumors were excised by primary surgery or primary reexcision and they were not accompanied by lymph node metastasis. Based on these data, complete tumor resection prior to chemotherapy should be pursued and the inguinal lymph nodes should be at least sampled because nodal involvement is closely associated with the patient's prognosis.

Entities:  

Mesh:

Year:  2005        PMID: 16308704     DOI: 10.1007/s00383-005-1592-5

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  13 in total

1.  Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.

Authors:  K S Baker; J R Anderson; M P Link; H E Grier; S J Qualman; H M Maurer; J C Breneman; E S Wiener; W M Crist
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

2.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.

Authors:  Poul H B Sorensen; James C Lynch; Stephen J Qualman; Roberto Tirabosco; Jerian F Lim; Harold M Maurer; Julia A Bridge; William M Crist; Timothy J Triche; Frederic G Barr
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

Review 3.  Issues in the local control of rhabdomyosarcoma.

Authors:  J C Breneman; E S Wiener
Journal:  Med Pediatr Oncol       Date:  2000-08

4.  Soft tissue sarcoma of the perineal region in childhood. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1972 through 1984.

Authors:  R B Raney; W Crist; D Hays; W Newton; F Ruymann; M Tefft; M Beltangady
Journal:  Cancer       Date:  1990-06-15       Impact factor: 6.860

5.  Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997).

Authors:  H L Neville; R J Andrassy; T E Lobe; C E Bagwell; J R Anderson; R B Womer; W M Crist; E S Wiener
Journal:  J Pediatr Surg       Date:  2000-02       Impact factor: 2.545

6.  Conservative management of uterine pediatric rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study III and IV pilot.

Authors:  C A Corpron; R J Andrassy; D M Hays; R B Raney; E S Wiener; W Lawrence; T E Lobe; H M Maurer
Journal:  J Pediatr Surg       Date:  1995-07       Impact factor: 2.545

7.  The effect of age at diagnosis on outcome in rhabdomyosarcoma.

Authors:  M P La Quaglia; G Heller; F Ghavimi; E S Casper; V Vlamis; S Hajdu; M F Brennan
Journal:  Cancer       Date:  1994-01-01       Impact factor: 6.860

8.  Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study.

Authors:  W A Newton; E A Gehan; B L Webber; H B Marsden; A J van Unnik; A B Hamoudi; M G Tsokos; H Shimada; D Harms; D Schmidt
Journal:  Cancer       Date:  1995-09-15       Impact factor: 6.860

9.  Primary reexcision for patients with 'microscopic residual' tumor following initial excision of sarcomas of trunk and extremity sites.

Authors:  D M Hays; W Lawrence; M Wharam; W Newton; F B Ruymann; M Beltangady; H M Maurer
Journal:  J Pediatr Surg       Date:  1989-01       Impact factor: 2.545

Review 10.  Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.

Authors:  Martin L Blakely; Richard J Andrassy; R Beverly Raney; James R Anderson; Eugene S Wiener; David A Rodeberg; Charles N Paidas; Thom E Lobe; William M Crist
Journal:  J Pediatr Surg       Date:  2003-03       Impact factor: 2.545

View more
  2 in total

1.  Soft tissue tumors of the anorectum: rare, complex and misunderstood.

Authors:  Mohammed O Nassif; Nora H Trabulsi; Kelli M Bullard Dunn; Ayoub Nahal; Ari-Nareg Meguerditchian
Journal:  J Gastrointest Oncol       Date:  2013-03

2.  Perianal and perineal rhabdomyosarcomas: a retrospective multicenter study of 35 cases.

Authors:  Yaoyu Guo; Bang Hu; Dandan Huang; Xinhua Wang; Juan Li; Di Zhang; Xueying Li; Gong Chen; Donglin Ren
Journal:  BMC Surg       Date:  2021-01-30       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.